Santiago de Compostela, Spain – Many cancer therapies, in addition to producing numerous side effects, fail to achieve complete tumour remission, partly due to the presence of cancer stem cells, which are difficult to eradicate. These cells can self-renew and play a key role in tumor recurrence and metastasis processes,...
treatment News
Cork, Ireland – A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails. . The recent study published in the prestigious Journal of Clinical Oncology (JCO) was led by Professor Jack Gleeson, Associate Professor at Cancer Research at...
LONDON, UK – In Gaucher disease, the toxic buildup of a fatty molecule called glucosylsphingosine (lyso-Gb1) leads to issues with how nerve cells generate energy and other cellular problems, according to a new study. Lyso-Gb1 is a biomarker of disease burden and response to treatment. The findings help to understand...
Pittsburgh, PA – Cancer patients who received specialized mental health support as part of their treatment plan are more likely to see improvements in their quality of life and reductions in pain, depression and fatigue, according to a study led by researchers at the University of Pittsburgh School of Medicine....
GRAND RAPIDS, Mich. — A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances. The preclinical research, led by Van Andel Institute scientists, determined how...
NATIONAL HARBOR, Md. – A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced the presentation of safety and early efficacy data from the EVEREST-2 study (NCT06051695) of its lead program, A2B694. The data was presented at the 40th Annual...
LOS ANGELES, Calif. — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, announced today that long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab-sirolimus in malignant PEComa were published in the Journal of...
SAN DIEGO, Calif. — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announces alignment with the U.S. Food and Drug Administration (FDA) on a protocol amendment to the company’s Phase 3...
SAN DIEGO, Calif. — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing...
SAN DIEGO, Calif. — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol...